Details of the Drug Combination

General Information of Drug Combination (ID: DC7SUJP)

Drug Combination Name

Articaine Mepivacaine

Indication

Disease Entry	Status	REF
Symptomatic Irreversible Pulpitis	Phase 2	[1]

Component Drugs

Articaine DM3NMT6

Mepivacaine DMH2NMY

Small molecular drug

2D MOL

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Articaine

Disease Entry	ICD 11	Status	REF
Anaesthesia	9A78.6	Approved	[2]

Indication(s) of Mepivacaine

Disease Entry	ICD 11	Status	REF
Analgesia	MB40.8	Approved	[2]

Mepivacaine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Blocker	[3]
------------------------------------------------------------------------------------

Mepivacaine Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Potassium voltage-gated channel subfamily KQT member 1 (KCNQ1)	OT8SPJNX	KCNQ1_HUMAN	Decreases Activity	[4]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03725579) Anesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
4	Long QT 1 mutation KCNQ1A344V increases local anesthetic sensitivity of the slowly activating delayed rectifier potassium current. Anesthesiology. 2006 Sep;105(3):511-20. doi: 10.1097/00000542-200609000-00015.